FDA Approves Emergent BioSolutions Winnipeg Facility for Raxibacumab Manufacturing
I'm PortAI, I can summarize articles.
Emergent BioSolutions Inc. has received FDA approval for its Winnipeg facility to manufacture raxibacumab, a monoclonal antibody for inhalational anthrax treatment. This approval enhances Emergent's manufacturing network and supports its transformation strategy by consolidating operations in Winnipeg and Lansing. The news was originally published by Emergent BioSolutions via GlobeNewswire on December 12, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments